I 3 Pharmaceuticals Revenue, Growth & Competitor Profile

Company Profile & Annual Report for I 3 Pharmaceuticals

Access the complete profile.

I 3 Pharmaceuticals Fast Facts

Revenue	$10 - $100 million    See Exact Annual Revenue
Employees	N/AExact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes	325412 Pharmaceutical Preparation Manufacturing
Address	200 Park Ave Warminster, PA 18974

Note: Revenues for privately held companies are statistical evaluations.


I 3 Pharmaceuticals's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • I 3 Pharmaceuticals's annual revenues are $10 - $100 million (see exact revenue data)
• What industry is the company in?
  • I 3 Pharmaceuticals is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

I 3 Pharmaceuticals Annual Revenue and Growth Rate

I 3 Pharmaceuticals	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	$10 - $100 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: I 3 Pharmaceuticals's revenues are gauged from an analysis of company filings.

I 3 Pharmaceuticals's Income Statement (based on Industry Averages)

I 3 Pharmaceuticals P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Investor Activity

I 3 Pharmaceuticals has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.

Date	Investors	Percent Raised	Target Size
May 23, 2022	1	100%	$16 MM
Complete list of funding rounds and total amounts in the Company Report

Market Share of I 3 Pharmaceuticals's Largest Competitors

A competitive analysis shows these companies are in the same general field as I 3 Pharmaceuticals, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to I 3 Pharmaceuticals. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
PEL HEALTHCARE	Sellersville, PA	100
LAMPIRE BIOLOGICAL LABS	Pipersville, PA	56
POWDERSIZE LLC DBA MICROSIZE	Quakertown, PA	35
I 3 PHARMACEUTICALS	Warminster, PA	23
PENN LIFE SCIENCES	Newtown, PA	13
EMERGEX USA	Doylestown, PA	12

Future Competition: I 3 Pharmaceuticals's Fastest Growing Competitors

These companies are in the same general field as I 3 Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)